142 related articles for article (PubMed ID: 31200842)
1. Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations.
Gandellini P; Casiraghi N; Rancati T; Benelli M; Doldi V; Romanel A; Colecchia M; Marenghi C; Valdagni R; Demichelis F; Zaffaroni N
Eur Urol Oncol; 2019 May; 2(3):277-285. PubMed ID: 31200842
[TBL] [Abstract][Full Text] [Related]
2. PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance.
Trock BJ; Fedor H; Gurel B; Jenkins RB; Knudsen BS; Fine SW; Said JW; Carter HB; Lotan TL; De Marzo AM
Mod Pathol; 2016 Jul; 29(7):764-71. PubMed ID: 27080984
[TBL] [Abstract][Full Text] [Related]
3. PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance.
Lokman U; Erickson AM; Vasarainen H; Rannikko AS; Mirtti T
Eur Urol Focus; 2018 Dec; 4(6):867-873. PubMed ID: 28753869
[TBL] [Abstract][Full Text] [Related]
4. Assessment of MYC/PTEN Status by Gene-Protein Assay in Grade Group 2 Prostate Biopsies.
Salles DC; Vidotto T; Faisal FA; Tosoian JJ; Guedes LB; Muranyi A; Bai I; Singh S; Yan D; Shanmugam K; Lotan TL
J Mol Diagn; 2021 Aug; 23(8):1030-1041. PubMed ID: 34062284
[TBL] [Abstract][Full Text] [Related]
5. Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.
Murphy SJ; Karnes RJ; Kosari F; Castellar BE; Kipp BR; Johnson SH; Terra S; Harris FR; Halling GC; Klein JL; Nasir A; Bergstrahl E; Rangel LJ; Sukov WR; Vasmatzis G; Cheville JC
Mod Pathol; 2016 Feb; 29(2):143-56. PubMed ID: 26612463
[TBL] [Abstract][Full Text] [Related]
6. PTEN Loss in Gleason Score 3 + 4 = 7 Prostate Biopsies is Associated with Nonorgan Confined Disease at Radical Prostatectomy.
Guedes LB; Tosoian JJ; Hicks J; Ross AE; Lotan TL
J Urol; 2017 Apr; 197(4):1054-1059. PubMed ID: 27693448
[TBL] [Abstract][Full Text] [Related]
7. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.
Böttcher R; Kweldam CF; Livingstone J; Lalonde E; Yamaguchi TN; Huang V; Yousif F; Fraser M; Bristow RG; van der Kwast T; Boutros PC; Jenster G; van Leenders GJLH
BMC Cancer; 2018 Jan; 18(1):8. PubMed ID: 29295717
[TBL] [Abstract][Full Text] [Related]
8. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.
Hamoen EHJ; Hoeks CMA; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Bokhorst LP; Witjes JA; Rovers MM; Hulsbergen-van de Kaa CA; Barentsz JO
Eur Urol Focus; 2019 May; 5(3):407-415. PubMed ID: 29331622
[TBL] [Abstract][Full Text] [Related]
9. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
[TBL] [Abstract][Full Text] [Related]
10. Associations Between iCOGS Single Nucleotide Polymorphisms and Upgrading in Both Surgical and Active Surveillance Cohorts of Men with Prostate Cancer.
Kearns JT; Lapin B; Wang E; Roehl KA; Cooper P; Catalona WJ; Helfand BT
Eur Urol; 2016 Feb; 69(2):223-8. PubMed ID: 26411806
[TBL] [Abstract][Full Text] [Related]
11. PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy.
Lotan TL; Carvalho FL; Peskoe SB; Hicks JL; Good J; Fedor H; Humphreys E; Han M; Platz EA; Squire JA; De Marzo AM; Berman DM
Mod Pathol; 2015 Jan; 28(1):128-137. PubMed ID: 24993522
[TBL] [Abstract][Full Text] [Related]
12. Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations.
Khani F; Wobker SE; Hicks JL; Robinson BD; Barbieri CE; De Marzo AM; Epstein JI; Pritchard CC; Lotan TL
J Pathol; 2019 Sep; 249(1):79-89. PubMed ID: 30993692
[TBL] [Abstract][Full Text] [Related]
13. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer.
Masic S; Cowan JE; Washington SL; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
Eur Urol Oncol; 2018 Oct; 1(5):386-394. PubMed ID: 31158077
[TBL] [Abstract][Full Text] [Related]
14. PTEN status assessment in the Johns Hopkins active surveillance cohort.
Tosoian JJ; Guedes LB; Morais CL; Mamawala M; Ross AE; De Marzo AM; Trock BJ; Han M; Carter HB; Lotan TL
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):176-181. PubMed ID: 30279579
[TBL] [Abstract][Full Text] [Related]
15. Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer.
Gillard M; Lack J; Pontier A; Gandla D; Hatcher D; Sowalsky AG; Rodriguez-Nieves J; Vander Griend D; Paner G; VanderWeele D
Eur Urol Focus; 2019 May; 5(3):433-442. PubMed ID: 29229583
[TBL] [Abstract][Full Text] [Related]
16. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
[TBL] [Abstract][Full Text] [Related]
17. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
Bismar TA; Yoshimoto M; Vollmer RT; Duan Q; Firszt M; Corcos J; Squire JA
BJU Int; 2011 Feb; 107(3):477-85. PubMed ID: 20590547
[TBL] [Abstract][Full Text] [Related]
18. Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.
Flood TA; Schieda N; Keefe DT; Breau RH; Morash C; Hogan K; Belanger EC; Mai KT; Robertson SJ
Virchows Arch; 2016 Sep; 469(3):313-9. PubMed ID: 27394432
[TBL] [Abstract][Full Text] [Related]
19. Spatial Intratumor Genomic Heterogeneity within Localized Prostate Cancer Revealed by Single-nucleus Sequencing.
Su F; Zhang W; Zhang D; Zhang Y; Pang C; Huang Y; Wang M; Cui L; He L; Zhang J; Zou L; Zhang J; Li W; Li L; Shao J; Ma J; Xiao F; Liu M
Eur Urol; 2018 Nov; 74(5):551-559. PubMed ID: 29941308
[TBL] [Abstract][Full Text] [Related]
20. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
